Ending Stagnation: How Collaboration Tools Are Enabling a New Era of R&D
By PolycomBiopharma R&D, from drug discovery through to late phase clinical trials, suffers from two fundamental, near industry-threatening problems: it is too slow and too expensive.
With payers and the public getting increasingly vocal about drug prices, the long-standing tactic of passing on costs to the healthcare system is precarious.
Download to find out more.